A statement of changes in beneficial ownership was filed on November 18, 2026, disclosing that Jeremy Murphy, a director of Research Solutions, Inc. (NASDAQ:RSSS), was granted options to purchase 12,500 shares of common stock on November 16, 2026.

Key Highlights

  • Reporting person: Jeremy Murphy, identified as a Director of Research Solutions, Inc.
  • Grant date: November 16, 2026, with options to purchase common stock at an exercise price of $1.89 per share.
  • Options granted: 12,500 options acquired (transaction code A) at a price of $0, expiring November 15, 2036.
  • Vesting schedule: One-third of the options vest on November 16, 2027; thereafter, one-twelfth vest on the last day of each quarter beginning December 31, 2027, until fully vested.
  • Resulting ownership: Murphy beneficially owned 12,500 derivative securities following the reported transaction, held directly.

Director Option Grant Details at Research Solutions

According to the filing, Jeremy Murphy holds the position of Director at Research Solutions, Inc., a company listed on NASDAQ under the ticker RSSS and headquartered in Henderson, Nevada. The filing was signed by David Kutil as Attorney-in-Fact on November 18, 2026, and covers a transaction dated November 16, 2026, as the date of earliest transaction.

The disclosed grant consists of options to purchase common stock, with a conversion or exercise price of $1.89 per share. The filing reports that 12,500 options were acquired at a derivative security price of $0, meaning no cash outlay was required by Murphy at the time of grant. The options carry an expiration date of November 15, 2036, giving a ten-year term from the grant date, as reported in the filing. Research Solutions operates as a provider of research management software and content solutions serving academic and corporate customers.

The vesting schedule noted in the filing's explanation of responses states that one-third of the options vest on November 16, 2027, and one-twelfth of the options vest on the last day of each quarter beginning December 31, 2027, continuing until fully vested. Following this transaction, the filing indicates Murphy directly and beneficially owned 12,500 derivative securities. No non-derivative securities were reported in Table I of the filing.

What Was Disclosed

The filing disclosed a director-level option grant to Jeremy Murphy covering 12,500 shares of Research Solutions, Inc. common stock at an exercise price of $1.89, with a ten-year term and a multi-year vesting schedule beginning in November 2027.